Determining the effect of hypothermia in improving peripheral neuropathy caused by chemotherapy drugs

Not Applicable

Recruiting

• Conditions: chemotherapy induced neuropathy.; Drug-induced polyneuropathy; G62.0

• Registration Number: IRCT20231108059991N1
• Lead Sponsor: Sabzevar University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Consent to use the cooling device and complete the consent form
The use of one of the chemotherapy regimens with the occurrence of neuropathy including drugs from the taxanes
Performance more than 70%
Age less than 75 years

Exclusion Criteria

History of melanoma
History of systemic lupus erythematosus
Poor controlled diabetes
Dissatisfaction with using the device
History of cryoglobulinemia

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of neuropathy. Timepoint: Measuring the severity of neuropathy at the beginning of the study (before the start of the intervention) and the 6th and 12th sessions of chemotherapy and 3 months after the end of the treatment. Method of measurement: European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Chemotherapy-Induced Peripheral Neuropathy (CIPN) 20.;Quality of Life. Timepoint: Measuring the severity of neuropathy at the beginning of the study (before the start of the intervention) and 3 months after the end of the treatment. Method of measurement: World Health Organization Quality of Life Questionnaire.